Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
Langetermijnresultaten van SABR bij operabel stadium I NSCLC
dec 2021 | Chirurgie, Longoncologie, Radiotherapie